Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress

Stock Track05-19

Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.

The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.

Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144972324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144972324","market":"us","top_or_hot":-1,"title":"Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress","media":"Stock Track","content":"<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.</p><p>The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.</p><p>Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"","article_id":"1144972324","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144972324","pubTimestamp":1779154765,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc."},"translate_title":"个股追踪|Zenas BioPharma因CEO购股及3期试验进展大涨9.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":1},"content_text":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that boosted investor confidence.The stock's upward movement was driven in part by news that CEO Leon O. Moulder Jr. purchased 60,000 common shares for approximately $1.01 million at a weighted average price of $16.88. This substantial insider buying, disclosed shortly before the price movement, signaled strong confidence from the company's leadership in Zenas BioPharma's future prospects.Additionally, the company announced advancements in its Phase 3 clinical trial for orelabrutinib, targeting the challenging multiple sclerosis segment. This positive development in the company's pipeline of transformative therapies for autoimmune diseases further contributed to the bullish sentiment among investors during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144972324","isCrawlerRequest":true}